Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Gideon M. Hirschfield, John M. Vierling et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 186
Tu1515: CLIMB: A PROSPECTIVE, BLINDED, MULTICENTER U.S. BASED STUDY EVALUATING A MULTI-ANALYTE BLOOD-BASED TEST FOR DETECTING HEPATOCELLULAR CARCINOMA (HCC) IN PATIENTS WITH LIVER CIRRHOSISDavid J. Taggart, Mindie H. Nguyen, Ziad Younes et al.|Gastroenterology|2025Cited by 1